Description
Ponatinix45 (Ponatinib) 45mg Online
Ponatinix45 (Ponatinib) is a medicine that targets proteins in cancer cells and stops the cancer cell from growing.
It is used to treat chronic myelogenous leukemia and certain types of acute lymphoblastic leukemia. Compare kinase inhibitors. Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated. Treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
The optimal dose of Ponatinib has not been identified. In clinical trials, the starting dose of Ponatinib was 45 mg administered orally once daily. However, in the phase 2 trial, 68% of the patients required dose reductions to 30 mg or 15 mg once daily during the course of therapy. Start dosing with 45 mg once daily. Consider reducing the dose of Ponatinib for patients with chronic phase (CP) CML and accelerated phase (AP) CML who have achieved a major cytogenetic response. Consider discontinuing Ponatinib if the response has not occurred in months(90 days). Ponatinib may be taken with or without food.
Arterial occlusions, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, the severe peripheral vascular disease have occurred in at least 35% of Ponatinib-treated patients from the phase 1 and phase 2 trials. With a minimum of 48 months follow-up for ongoing patients (N=133) in the phase 2 trial, 33% (150/449) of Ponatinib treated patients experienced a cardiac vascular (21%), peripheral vascular (12%), or cerebrovascular (9%) arterial occlusive event; some patients experienced more than 1 type of arterial occlusive event.
